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Abstract
Background: Infection by Extended Spectrum Beta Lactamases (ESBLs) producing bacteria is a threat to man as a consequence of treatment
challenges. This study evaluated the prevalence and antimicrobial susceptibility pattern of ESBL producing Klebsiellae (EPK) in clinical specimens
at the University of Ilorin Teaching hospital, Ilorin (UITH), Nigeria.
Methods: ESBL production was assayed using Double Discs Synergy Test (DDST). Antimicrobial susceptibility was performed by Modified Kirby-
Baeur method with the organism tested against ceftazidime (30µg), cefotaxime (30µg), amoxicillin-clavulinic acid (20/10µg), cefepime (30µg),
ciprofloxacin (5µg), gentamicin (10µg), trimethoprim-sulphamethoxazole (23.75/1.25µg), imipenem (10µg) and doripenem (10µg) (Oxoid, UK).
Results: Fifty (26.7%) of the 187 Klebsiellae studied were EPK comprising of 37(26.8%) Klebsiella pneumoniae and 13(26.5%) Klebsiella oxytoca.
EPK were mostly from wound specimens (24.0%) although Klebsiellae were mostly occurring in sputum (26.2%). The EPK were resistant to
ceftazidime (100%), cefotaxime (94.0%), trimethoprim-sulphamethoxazole (92.0%), gentamicin (70.0%) and ciprofloxacin (70.0%) but 100%
susceptible to both doripenem and imipenem.
Conclusion: The prevalence of EPK in this study is high and they are multi-drug resistant. Carbapenems are the best antibiotic treatment option for
infections arising from these organisms although a coordinated rational usage is desired along with functional antibiotic prescription policy to avoid
treatment failures. Continuous surveillance for ESBL producing Klebsiellae and resistance monitoring are necessary routine to strengthen infection
control policies.
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Introduction
Klebsiella species and Escherichia coli have been reported to harbor ESBL enzyme with K. pneumoniae being the most frequent isolate
(Paterson and Bonomo, 2005). Klebsiella spp are involved in various infections affecting both immunocompetent and immunocompromised hosts
with a wide spectrum involving urinary, respiratory and gastro intestinal tracts. In addition, they cause bacteremia, septicaemia, and various organ
and soft tissue infections. ESBL producing Klebsiella spp have emerged as a major problem in hospitalized as well as community based patients as a
result of the difficulty it poses to treatment (Paterson et al., 2003). Extended Spectrum Beta Lactamase (ESBL) producing organisms breakdown
penicillins and cephalosporins, through the production of β-lactamases capable of hydrolyzing the β-lactam ring of these drugs (Bradford, 2001).  
The first ESBL isolates were discovered in Germany in the mid-1980s and subsequently in the United States of America in the late 1980s shortly
after the introduction of ceftazidime and cefotaxime into clinical practice (Knothe et al., 1983). The emergence and spread of ESBL producing
organisms is believed to be due to the dissemination of clones of some epidemic strains as well as horizontal transmission of resistance gene-carrying
plasmids among bacterial organisms (Rodriquez-Bano et al., 2004). The rise in the use of second and third generation cephalosporins to treat
infections have similarly led to the development and selection of multiple drug resistant bacteria like ESBL producers (Pitout and Laupland, 2008).
These organisms often acquire resistance to non-β-lactam antibiotics including aminoglycosides and fluoroquinolones, resulting in multi-drug 
resistant properties.
Risk factors that have been associated with infection or colonization with ESBL producing organisms including Klebsiella strains are
prolonged hospitalization, stay in nursing homes, use of invasive devices (e.g., urinary catheters, central venous lines, and endotracheal tubes), and
use of antibiotics belonging to third-generation cephalosporins, fluoroquinolones, and aminoglycosides group (Paterson, 2000). The burden of
antibiotic resistance including the ESBL phenotypes cannot be over- emphasized especially in neonates, children and the immune -compromised as it
leads to an increased risk of death, length of stay in hospitals and cost of care (Schwaber M et al., 2006 ).
In recent times, EPK showing multi-drug resistance features are being isolated in many laboratories. It is therefore necessary to search in
every setting for this organism which has constituted itself into a threat to man consequent upon its treatment challenges. It is similarly important to
define the best choice of antibiotic therapy for the infections caused by EPK with the sole aim of reducing the length of patient stay in hospitals, cost
of treatment and rates of mortality and morbidity which is the primary focus of this study.
Materials and Methods
This study was done at the UITH Medical Microbiology laboratory. Ethical clearance was obtained from the Ethical committee of the
institution. One hundred and eighty seven (187) clinical isolates of Klebsiella were obtained non-repetitively from different clinical specimens
including blood, sputum, wound, urine, ear, eye and throat swabs between October, 2013 and February, 2014. .
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Re- characterization and Storage of Isolates
The organisms were re-characterized using standard microbiological techniques (Cheesebrough, 2006). Identified Klebsiella isolates were
stored at -20oC using 20% Brain heart infusion (BHI)-glycerol broth until further processed.
ESBL Detection
                ESBL production was assayed by the double disc synergy test (DDST) method. Briefly, 30 μg of ceftazidime dics (Oxoid, UK) was placed 
at a distance of 20 mm (edge to edge) from an amoxicillin-clavulinic acid disc (20/10 μg, Oxoid, UK) on Mueller-Hinton agar plate already 
inoculated with the test organism. Inoculum was prepared by suspending the test organism in sterile physiologic saline inside Bijou bottle and
adjusting its turbidity to that of 0.5 McFarland standards. Inoculation was done by rolling the cotton swabs, previously dipped into the inoculum
suspension with the excess fluid removed by compressing the swab against the inside wall of the container, on the surface of the Mueller-Hinton
agar. The set-up was incubated at 35oC for 16-18 hours. (CLSI, 2013) Escherichia coli ATCC 25922 was used as negative control. Positive test
consisted of enhancement/amplification of inhibition zone around ceftazidime and towards amoxicillin/clavulinic acid disc giving a dump-bell
appearance.
Antimicrobial Susceptibility testing
This was done using the modified Kirby Baeur-Method. Inoculum preparation, inoculation and incubation were done as described under
assay for ESBL. The antibiotics discs ( Oxoid, UK products) used were gentamicin (10µg), ciprofloxacin (5µg), trimethropin- sulphamethoxazole
(1.25/23.75µg), cefepime (30µg), amoxicillin-long clavulinic acid (20/10µg), cefotaxime (30µg), ceftazidime (30µg), imipenem (10 µg) and
doripenem (10 µg ). The discs were placed on the inoculated Mueller-Hinton agar at a distance of 15mm from the edge of an inoculated plate and
about 25 mm from disc to disc. A maximum of 6 discs were placed on a 90mm petri dish. Within 30mins of applying the discs, the plates were
inverted and incubated aerobically at 350C for 16– 18hours. Escherichia coli ATCC 25922 was used as control. Zones of inhibition were recorded
with a meter rule and results were interpreted as sensitive (S), intermediate (I) and resistant (R) according to CLSI standard.
Data analysis
Data were entered into the computer using excel spread sheet and statistical analysis was performed using Microsoft excel (2007) and the
Statistical Product and Service Solutions (SPSS) software version 19.0 (IBM SPSS, 2012).
Results
Of the 187 Klebsiella isolates examined, 138 (73.8%) were Klebsiella pneumoniae and the remainder Klebsiella oxytoca, 49(26.2%). In all,
50 (26.7%) of the Klebsiella isolates were EPK comprising of 37(74%) Klebsiella pneumoniae and 13(26%) Klebsiella oxytoca (Table 1).
Table 2 shows the distribution of EPK according to specimens while table 3 shows distribution according to wards. Klebsiella isolates (26.2%) were
mostly isolated from sputum but EPK were mostly found in wound culture specimens (24.0%). Majority (75%) of the Klebsiella isolates from the
ICU were EPK.
Table 4 showed the antimicrobial susceptibility pattern of EPK. The EPK were multi-drug resistant being resistant to ceftazidime (100%),
cefotaxime (94.0%), and trimethoprim-sulphamethoxazole (92.0%) among others. They were largely susceptible to carbapenems displaying no
resistance against doripenem (0%) and imipenem (0%) but one isolate is intermediately susceptible to imipenem.
Figure 1 shows the dump-bell shaped inhibition zone around ceftazidime and towards amoxicillin-clavulinic acid disc which is characteristic of
ESBL producers.
Table 1: Prevalence of ESBL producing Klebsiella spp
Organism Total Number (%) Number of ESBL Producers (%)
Klebsiella oxytoca 49 (26.2) 13 (26)
Klebsiella pneumoniae 138 (73.8) 37 (74)
Total 187 (100) 50 (100)
Discussion
The prevalence of EPK in this study was 26.7%. This result was similar to the study done in Enugu (Ejikeugwu et al., 2013) Nigeria, and
that of Iran (Shanyanfar et al., 2010) where prevalence rates of 26.0% and 27.0% were obtained respectively. A slightly higher prevalence of 36.6%
was obtained in Benin (Ozazuwa and Ozazuwa, 2013). Much higher prevalence rates of 43.2% in Ibadan (Okesola and Oni, 2012), and 51.3% in Ile
Ife (Olowe et al., 2012), all in Nigeria, have been documented.
The high rates of EPK being globally reported is a major concern not only to healthcare givers but the general populace. EPK infections
have impacted negatively on mankind constituting a special health and economic burden due to increased morbidity and mortality, increase in
hospital stay and cost of treatment (Okonko et al., 2009a). High prevalence of ESBL production by bacteria has been associated with the irrational/
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overuse of penicillins and cephalosporins in our environment (Akande et al., 2009) indicating the need for development and enforcement of an
antibiotic prescription policy. Continuous surveillance through well-equipped laboratories for prompt accurate detection and reporting of EPK should
also become a routine in our hospitals as a guide to functional infection control interventions.
Table 2: Specimen distribution of ESBL producing Klebsiella spp
Specimen Klebsiella Isolates collected ESBL producers n(%)
Aspirate 13(7.0) 7 (14.0)
Blood 17(9.1) 4(8.0)
Ear swab 6(3.2) 1(2.0)
Eye swab 4(2.1) 1(2.0)
Lochia 1(0.5) 1(2.0)
Pus 4(2.1) 2(4.0)
Sputum 49(26.2) 6(12.0)
Throat swab 2(1.1) 2(4.0)
Urine 28(15.0) 6(12.0)
Urine catheter tip 6(3.2) 3(6.0)
UVC tip 13(7.0) 5(10.0)
Wound aspirate 1(0.5) 0(0)
Wound biopsy 1(0.5) 0(0)
Wound swab 42(22.5) 12(24.0)
Total 187(100) 50(100)
Table 3: Ward Distribution of ESBL producing Klebsiella isolates
Ward Isolates collected, n(%) ESBL producers, n(%)
A/E 35(18.7) 7 (14.0)
CHEST 1(0.5) 1(2.0)
DENTAL 1(0.5) 1(2.0)
ENT 3(1.6) 1(2.0)
EPU 12(6.4) 1(2.0)
EYE 1(0.5) 0(0)
GYNAE 12(6.4) 4(8.0)
ICU 4(2.1) 3(6.0)
MW 22(11.8) 7(14.0)
NICU 19(10.2) 6(12.0)
OPD 31(16.6) 3(6.0)
STROKE 6(3.2) 4(8.0)
SW 21(11.2) 7(14.0)
OTHERS 19(10.2) 5(10.0)
Total 187(100) 50(100)
A/E- Accident and Emergency, ENT- Ear Nose and Throat, EPU-Emergency Paediatric Unit, ICU-Intensive Care
Unit, MW-Medical Ward, NICU-Neonatal Intensive Care Unit, OPD-Out-Patient Dept, SW-Surgical ward
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Figure 1: Dump-bell inhibition zone of positive DDST characteristic of ESBL producing Klebsiellae
Table 4: Antibiotic Susceptibility pattern of ESBL producing Klebsiella spp
Lower prevalence rates of ESBL producing Klebsiella however of 5.0% was reported in Ogun (Olowe et al., 2010) and 13.8% in Nsukka
(Afunwa et al., 2011), all in Nigeria. It is difficult to explain the variations in the prevalence rates although it may not be unconnected to study design
and detection techniques used in the different studies.
Antibiotics
ESBL producers. n=50
Klebsiella spp
n=50
K.oxytoca,
n=13
K.pneumoniae,
n=37
Cefotaxime S (%) 0 0 0
I (%) 0 0 0
R (%) 100 100 100
Ceftazidime S (%) 0 0 0
I (%) 6.0 0 8.1
R (%) 94.0 100 91.9
Amox-clav S (%) 6.0 7.7 5.4
I (%) 28.0 38.5 24.3
R (%) 66.0 53.8 70.3
Cefepime S (%) 30.0 15.4 35.1
I (%) 50.0 61.5 45.9
R (%) 20.0 23.1 18.9
Gentamicin S (%) 20.0 7.7 24.3
I (%) 10.0 15.4 8.1
R (%) 70.0 76.9 67.6
Ciprofloxacin S (%) 14.0 7.7 16.2
I (%) 16.0 7.7 18.9
R (%) 70.0 84.6 64.9
TMP-SMX S (%) 6.0 0 8.1
I (%) 2.0 0 2.7
R (%) 92.0 100 89.2
Imipenem S (%) 98.0 100 97.3
I (%) 2.0 0 2.7
R (%) 0 0 0
Doripenem S (%) 100 100 100
I (%) 0 0 0
R (%) 0 0 0
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In this study, the ratio of occurrence of Klebsiella pneumoniae to Klebsiella oxytoca was approximately 3:1. This agrees with de
la Torre et al. (de la Torre et al., 1985 ) who had stated that Klebsiella infections are caused mainly by K.pneumoniae and K.oxytoca in the ratio of
4:1. This finding may be related to the pathogenic potentials and hence medical importance of these species of Klebsiella compared with others
(Podschun and Ullmann, 1998).
The rate of isolation of ESBL producing Klebsiellae was highest from infected wounds (24%) in this study. This contrasted with
the findings of Okesola and Oni (2012), and Olowe et al (2012) who reported 42.1% and 24.3% of EPK isolation rates respectively from sputum
indicating the lungs as the major infected organ source of the organism in their own studies. The reason for this deviation is difficult to decipher,
hence further studies will be needed to clarify this issue.
As found in this study, 75% of Klebsiellae from the Intensive Care Unit (ICU) in our hospital were EPK. Shanfayar et al. (2010)
had documented a high (100%) ESBL producing Klebsiella isolation rates from the ICU. ESBL producing organisms can easily spread among ICU
patients via the hands of health care practitioners and hospital equipment (Bermudes et al., 1995). In the same light, Fillipa et al (2013) documented
an outbreak of ESBL producing bacteria among ICU patients in France whose origin was traced to a patient transferred to the ICU from Nigeria.
These findings suggest the need for special infection control measures and antibiotics usage in our ICUs.
ESBL producing Klebsiella organisms in this study were multi-drug resistant. Most common locally available antimicrobial were
inactive against EPK given their resistance levels: cefotaxime (100%), ceftazidime (94%), trimethroprin-sulphamethoxazole (92%), gentamicin
(70%), ciprofloxacin (70%) and amoxicillin-clavulanate (66%). Characteristically peculiar to multi-drug resistant organisms, the ESBL producing
Klebsiella in this study were not only resistant to β-lactam drugs but non-β-lactam antibiotics like the aminoglycosides and fluoroquinolones as well 
(Okonko et al., 2009a). The high rates of resistance to antibiotics have been linked to the pressure of antibiotic usage. This has selective effect on
resistant strains and promotes its spread. The multi-drug resistant organisms are now major public health concern as they limit the available drugs
that can be used to treat infections (Pitout and Laupland, 2008).
Although cefepime showed considerable activity against ESBL producing Klesiellae in this study, CLSI (2013) recommends that
in-vitro results of all penicillins and cephalosporins should be reported as resistant for ESBL isolates of E.coli and Klebsiella species irrespective of
their individual test results. Therefore, cefepime may not demonstrate reasonable therapeutic effect in-vivo and should be used with caution in the
management of ESBL producing Klebsiellae infections in our area where poverty could impair the use of the proven and recommended carbapenems
due to cost.
All the EPK examined in this study were sensitive to doripenem with only 2% displaying intermediate susceptibility to
imipenem. Carbapenems therefore remain the best treatment option for infections caused by ESBL producing Klesiellae in our setting as elsewhere.
One possible explanation for the perceived activity of the carbapenems in our locality is its late arrival in the Nigerian market. Ensuring its continued
relevance as a treatment option for the Nigerian patient hence will require a coordinated rational usage given the emergence of carbapenemases in
some regions of the world. Judicious use of carbapenems should be a composite part of a functional antibiotic prescription policy which is lacking in
most African countries to avoid treatment failures
Conclusion
The prevalence of EPK in this study is high and they are generally multi-drug resistant. Carbapenems however remain the most useful
therapy for the infections caused by these organisms. A coordinated rational usage of carbapenems and functional antibiotic prescription policy is
desired to avoid treatment failures. Continuous surveillance through well-equipped laboratories for prompt accurate detection and reporting of EPK
as well as identification of multi-drug resistance should equally become a routine in our hospitals.
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